RATIONALE: There is evidence that prefrontal lobe GABA levels are low in cocaine-dependent (CD) individuals, and treatment with GABA agonists decreases cocaine self-administration. OBJECTIVES: The aim of the study is to measure changes in GABA levels in CD subjects at baseline and after 8 weeks of treatment with pramipexole, venlafaxine, or placebo. METHODS:CD subjects enrolled in a treatment trial for cocaine dependence were recruited for this proton (1H) magnetic resonance spectroscopy (MRS) study. GABA levels in the prefrontal lobe were measured before and after treatment. RESULTS: Mean percentage changes in GABA levels were as follows: pramipexole +17.0+/-28.0%, venlafaxine +13.0+/-11.0%, and placebo -2.1+/-19.5%. Pramipexole-treated subjects had significantly increased brain GABA levels compared to placebo (p=0.031). Venlafaxine treatment was nonsignificantly associated with increased GABA levels compared to placebo (p=0.16). The overall statistical model for the effect of drug treatment vs placebo on brain GABA levels, including adjustment for baseline levels, was highly significant (p=0.002). Despite significant changes in GABA levels, there were no significant differences in the number of urine samples positive for cocaine metabolites. CONCLUSIONS: This study demonstrates that 1H MRS can measure changes in GABA levels following pharmacologic treatment. The increase in GABA levels, although significant, is modest compared to other MRS studies of depression or epilepsy associated with clinical improvements. The failure to see larger increases in GABA levels and an associated reduction in cocaine consumption may reflect the relatively low doses of medication used.
RCT Entities:
RATIONALE: There is evidence that prefrontal lobe GABA levels are low in cocaine-dependent (CD) individuals, and treatment with GABA agonists decreases cocaine self-administration. OBJECTIVES: The aim of the study is to measure changes in GABA levels in CD subjects at baseline and after 8 weeks of treatment with pramipexole, venlafaxine, or placebo. METHODS:CD subjects enrolled in a treatment trial for cocaine dependence were recruited for this proton (1H) magnetic resonance spectroscopy (MRS) study. GABA levels in the prefrontal lobe were measured before and after treatment. RESULTS: Mean percentage changes in GABA levels were as follows: pramipexole +17.0+/-28.0%, venlafaxine +13.0+/-11.0%, and placebo -2.1+/-19.5%. Pramipexole-treated subjects had significantly increased brain GABA levels compared to placebo (p=0.031). Venlafaxine treatment was nonsignificantly associated with increased GABA levels compared to placebo (p=0.16). The overall statistical model for the effect of drug treatment vs placebo on brain GABA levels, including adjustment for baseline levels, was highly significant (p=0.002). Despite significant changes in GABA levels, there were no significant differences in the number of urine samples positive for cocaine metabolites. CONCLUSIONS: This study demonstrates that 1H MRS can measure changes in GABA levels following pharmacologic treatment. The increase in GABA levels, although significant, is modest compared to other MRS studies of depression or epilepsy associated with clinical improvements. The failure to see larger increases in GABA levels and an associated reduction in cocaine consumption may reflect the relatively low doses of medication used.
Authors: Gerard Sanacora; Graeme F Mason; Douglas L Rothman; Fahmeed Hyder; James J Ciarcia; Robert B Ostroff; Robert M Berman; John H Krystal Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: Changho Choi; Nicholas J Coupland; Christopher C Hanstock; Catherine J Ogilvie; Andrea C M Higgins; Dan Gheorghiu; Peter S Allen Journal: Magn Reson Med Date: 2005-08 Impact factor: 4.668
Authors: E Arvat; B Maccagno; J Ramunni; L Di Vito; L Gianotti; F Broglio; A Benso; R Deghenghi; F Camanni; E Ghigo Journal: Neuroendocrinology Date: 1998-05 Impact factor: 4.914
Authors: Xiaoxu Liu; J Eric Jensen; Timothy E Gillis; Chun S Zuo; Andrew P Prescot; Melanie Brimson; Kenroy Cayetano; Perry F Renshaw; Marc J Kaufman Journal: Psychopharmacology (Berl) Date: 2011-04-15 Impact factor: 4.530
Authors: Marisa M Silveri; Jennifer T Sneider; David J Crowley; Michael J Covell; Deepa Acharya; Isabelle M Rosso; J Eric Jensen Journal: Biol Psychiatry Date: 2013-03-14 Impact factor: 13.382
Authors: Richard De La Garza; Todd Zorick; Keith G Heinzerling; Steve Nusinowitz; Edythe D London; Steven Shoptaw; David E Moody; Thomas F Newton Journal: Pharmacol Biochem Behav Date: 2009-08-19 Impact factor: 3.533